[go: up one dir, main page]

IL131126A - Compositions for reducing the incidence of necrotizing enterocolitis and the preparation thereof - Google Patents

Compositions for reducing the incidence of necrotizing enterocolitis and the preparation thereof

Info

Publication number
IL131126A
IL131126A IL13112698A IL13112698A IL131126A IL 131126 A IL131126 A IL 131126A IL 13112698 A IL13112698 A IL 13112698A IL 13112698 A IL13112698 A IL 13112698A IL 131126 A IL131126 A IL 131126A
Authority
IL
Israel
Prior art keywords
incidence
compositions
reducing
necrotizing enterocolitis
preparation
Prior art date
Application number
IL13112698A
Other languages
English (en)
Other versions
IL131126A0 (en
Original Assignee
Abbott Lab
Univ Tennessee Res Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27420004&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL131126(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/943,576 external-priority patent/US6080787A/en
Application filed by Abbott Lab, Univ Tennessee Res Corp filed Critical Abbott Lab
Priority to IL15049098A priority Critical patent/IL150490A0/xx
Publication of IL131126A0 publication Critical patent/IL131126A0/xx
Publication of IL131126A publication Critical patent/IL131126A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
IL13112698A 1997-02-21 1998-02-19 Compositions for reducing the incidence of necrotizing enterocolitis and the preparation thereof IL131126A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL15049098A IL150490A0 (en) 1997-02-21 1998-02-19 A process for the production of an enteral formula containing arachidonic acid and/or docosahexaenoic acid in the form of phospholipids and formula obtained by same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80470097A 1997-02-21 1997-02-21
US82531497A 1997-03-28 1997-03-28
US08/943,576 US6080787A (en) 1997-02-21 1997-10-03 Methods for reducing the incidence of necrotizing enterocolitis
PCT/US1998/003235 WO1998036745A2 (fr) 1997-02-21 1998-02-19 Procede et compositions servant a limiter la frequence de l'enterocolite necrosante du nouveau-ne

Publications (2)

Publication Number Publication Date
IL131126A0 IL131126A0 (en) 2001-01-28
IL131126A true IL131126A (en) 2003-04-10

Family

ID=27420004

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13112698A IL131126A (en) 1997-02-21 1998-02-19 Compositions for reducing the incidence of necrotizing enterocolitis and the preparation thereof

Country Status (23)

Country Link
US (1) US6306908B1 (fr)
EP (1) EP1039892B1 (fr)
JP (1) JP2001516343A (fr)
CN (1) CN1200701C (fr)
AT (1) ATE265207T1 (fr)
AU (1) AU732903B2 (fr)
BR (1) BR9807443A (fr)
CA (1) CA2281706C (fr)
DE (1) DE69823548T2 (fr)
DK (1) DK1039892T3 (fr)
ES (1) ES2219871T3 (fr)
HU (1) HUP0300236A3 (fr)
ID (1) ID22744A (fr)
IL (1) IL131126A (fr)
NO (1) NO994052L (fr)
NZ (1) NZ337039A (fr)
PL (1) PL343902A1 (fr)
PT (1) PT1039892E (fr)
RU (1) RU2199317C2 (fr)
SK (1) SK112399A3 (fr)
TR (1) TR199902023T2 (fr)
TW (1) TWI230607B (fr)
WO (1) WO1998036745A2 (fr)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121165A0 (en) * 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
US6180671B1 (en) * 1998-03-10 2001-01-30 Beth Israel Deaconess Medical Center, Inc. Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected
DE19836339B4 (de) * 1998-08-11 2011-12-22 N.V. Nutricia Kohlenhydratmischung
US20090274660A1 (en) * 1999-08-17 2009-11-05 Immunopath Profile, Inc. Pluripotent therapeutic compositions and uses thereof
US6495599B2 (en) * 2000-04-13 2002-12-17 Abbott Laboratories Infant formulas containing long-chain polyunsaturated fatty acids and uses therof
GB0016045D0 (en) * 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
EP1542670B2 (fr) * 2002-09-24 2023-07-05 Suntory Holdings Limited Composition contenant de l'acide arachidonique seul ou en combinaison avec de l'acide docosahexanoique utile pour ameliorer les capacites cognitives chez l'adulte
US7323206B1 (en) 2003-03-04 2008-01-29 B. Braun Medical Inc. Reagents and methods for all-in-one total parenteral nutrition for neonates and infants
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
ES2326481T3 (es) * 2003-06-23 2009-10-13 Nestec S.A. Formula para recien nacidos o formula de continuacion.
CA2530170A1 (fr) * 2003-06-24 2005-01-06 University Of Kansas Medical Center Formule pour bebes
ES2304094B2 (es) 2003-08-18 2010-10-14 Btg International Limited Tratamiento de dolencias neurodegenerativas.
EP1597978A1 (fr) * 2004-05-17 2005-11-23 Nutricia N.V. Synergie de GOS et polyfructose
US8252769B2 (en) 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
US20080015166A1 (en) * 2004-06-22 2008-01-17 N.V. Nutricia Barrier Integrity in Hiv Patients
EP1721611A1 (fr) * 2005-04-21 2006-11-15 N.V. Nutricia Supplément nutritionnel avec des oligosaccharides pour une catégorie de patients avec HIV
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
EP1656839A1 (fr) 2004-11-11 2006-05-17 N.V. Nutricia Nutrition contenant un mélange de lipide
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
GB0504362D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
US20060233762A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
US7303745B2 (en) 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
ATE471665T1 (de) * 2005-04-21 2010-07-15 Nutricia Nv Nahrungsergänzungsmittel für hiv-patienten
CA2604383C (fr) * 2005-04-27 2014-09-09 N.V. Nutricia Nutrition avec des lipides et des saccharides non digestibles
CA2645647C (fr) 2005-05-23 2016-07-12 Massachusetts Institute Of Technology Compositions a base d'acides gras polyinsatures et/ou d'uridine et procedes d'utilisation correspondants
JP2007063219A (ja) * 2005-09-01 2007-03-15 Juntendo 新生児壊死性腸炎疾患予防剤
EP1776877A1 (fr) * 2005-10-21 2007-04-25 N.V. Nutricia Méthode de stimulation de la flore intestinale
US7829126B2 (en) 2005-10-26 2010-11-09 Abbott Laboratories Infant formulas containing docosahexaenoic acid and lutein
US20070166354A1 (en) * 2005-10-26 2007-07-19 Bridget Barrett-Reis Method of reducing the risk of retinopathy of prematurity in preterm infants
US20070149617A1 (en) 2005-11-14 2007-06-28 Deckelbaum Richard J Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs
EP1973424B1 (fr) * 2005-12-23 2019-09-11 N.V. Nutricia Compositions nutritionnelles destinees a prevenir l'obesite
US20080003330A1 (en) * 2006-06-30 2008-01-03 Ricardo Rueda Infant formulas for early brain development
US20080003329A1 (en) * 2006-06-30 2008-01-03 Ricardo Rueda Enriched infant formulas
US7867542B2 (en) * 2006-11-02 2011-01-11 Ach Food Companies, Inc. Non-flammable release composition
EP2200443B2 (fr) 2007-09-17 2021-06-30 Cornell University Acides gras à chaîne ramifiée pour la prévention ou le traitement de troubles gastro-intestinaux
ES2426591T5 (es) † 2007-10-09 2017-08-16 Enzymotec Ltd. Composiciones de lípidos para el tratamiento de trastornos gastrointestinales
UY31410A1 (es) * 2007-10-30 2009-05-29 Composicion que comprende acidos grasos poliinsaturados y carbon vegetal activado
CN103202353A (zh) 2007-11-01 2013-07-17 恩兹默泰克有限公司 用于婴儿营养的脂质混合物
US8361534B2 (en) * 2007-12-20 2013-01-29 Abbott Laboratories Stable nutritional powder
AU2008343689A1 (en) * 2007-12-20 2009-07-09 Abbott Laboratories Stable nutritional powder
EP2100897A1 (fr) * 2008-01-30 2009-09-16 BNLfood Investments SARL Composition à base de lécithine et son utilisation dans les aliments
WO2009096772A1 (fr) * 2008-02-01 2009-08-06 N.V. Nutricia Composition stimulant l'activité des cellules tueuses naturelles
US9737213B1 (en) * 2009-03-24 2017-08-22 Vioptix, Inc. Using an oximeter probe to detect intestinal ischemia
MY161505A (en) * 2009-04-01 2017-04-14 Nestec Sa Reduction of risk of obesity
TW201112967A (en) 2009-09-16 2011-04-16 Abbott Lab Dryblended nutritional powders
TW201121431A (en) * 2009-12-01 2011-07-01 Abbott Lab Soy protein-based nutritional formula with superior stability
TWI492744B (zh) 2009-12-04 2015-07-21 Abbott Lab 使用類胡蘿蔔素調節早產兒發炎症之方法
US9226521B2 (en) * 2009-12-08 2016-01-05 Nestec S.A. Infant formula with probiotics and milk fat globule membrane components
NZ601141A (en) * 2010-01-19 2014-07-25 Abbott Lab Nutritional formulas containing synbiotics
PE20121730A1 (es) 2010-01-29 2013-01-13 Abbott Lab Liquidos nutricionales envasados asepticamente que comprenden beta-hidroxi-beta-metilbutirato (hmb)
ES2481865T3 (es) 2010-01-29 2014-07-31 Abbott Laboratories Emulsiones nutricionales que comprenden HMB de calcio
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
EP2397038A1 (fr) 2010-06-21 2011-12-21 Abbott Laboratories Programmation précoce de la fonction cérébrale au moyen de l'alimentation aux protéines de soja
WO2012009426A1 (fr) 2010-07-13 2012-01-19 Abbott Laboratories Préparation à haute tolérance pour nourrissons comprenant des protéines hydrolysées
EP2422629A1 (fr) 2010-08-23 2012-02-29 Abbott Laboratories Méthode pour améliorer les performances cognitives et/ou la mémoire utilisant les maltodextrines
WO2012027287A1 (fr) 2010-08-24 2012-03-01 Abbott Laboratories Produits nutritionnels comprenant des hydrolysats de protéines de pois
EP2984941A1 (fr) 2010-08-24 2016-02-17 Abbott Laboratories Produits nutritionnels présentant des propriétés organoleptiques améliorées
CA2821319A1 (fr) 2010-12-29 2012-07-05 Abbott Laboratories Produits nutritionnels contenant des monoglycerides et des acides gras
BR112013016587A2 (pt) 2010-12-31 2016-09-27 Abbott Lab formulações nutricionais incluindo oligossacarídeos de leite humano e antioxidantes e usos das mesmas
MX355780B (es) 2010-12-31 2018-04-30 Abbott Lab Fórmula pediátrica sintética para estimular células nerviosas entéricas en el tracto gastrointestinal.
CN103763940B (zh) 2010-12-31 2015-10-14 雅培制药有限公司 促进有益微生物群生长的益生菌和人乳寡糖的合益素组合
MY180910A (en) 2010-12-31 2020-12-11 Abbott Lab Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
MY171620A (en) 2010-12-31 2019-10-21 Abbott Lab Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers or children using human milk oligosaccharides
EP3510873A1 (fr) 2010-12-31 2019-07-17 Abbott Laboratories Compositions nutritionnelles comprenant des oligosaccharides et nucléotides du lait humain et leurs utilisations pour traiter et/ou prévenir l'infection virale entérique
MY166946A (en) 2010-12-31 2018-07-25 Abbott Lab Methods of using human milk oligosaccharides for improving airway respiratory health
CA2822222C (fr) 2010-12-31 2019-05-07 Abbott Laboratories Oligosaccharides de lait humain pour moduler l' inflammation
WO2013012989A2 (fr) 2011-07-19 2013-01-24 The Trustees Of Columbia University In The City Of New York Procédé et système de production d'hydrogène et de monoxyde de carbone
WO2013016111A1 (fr) 2011-07-22 2013-01-31 Abbott Laboratories Galacto-oligosaccharides pour prévenir une lésion et/ou favoriser la cicatrisation du tractus gastro-intestinal
MX368124B (es) 2011-08-29 2019-09-19 Abbott Lab Oligosacaridos de leche humana para prevenir lesion y/o promover cicatrizacion del tracto gastrointestinal.
US20140335259A1 (en) 2011-12-29 2014-11-13 Abbott Laboratories Methods for reducing microbial contamination of dryblended powdered nutritional compositions
WO2013101516A1 (fr) 2011-12-29 2013-07-04 Abbott Laboratories Procédés pour la diminution de l'incidence d'entérocolite nécrosante chez des nourrissons, des tout-petits ou des enfants à l'aide d'adn génomique extrait
US20150064220A1 (en) 2012-03-27 2015-03-05 Abbott Laboratories Methods for modulating cell-mediated immunity using human milk oligosaccharides
WO2013170189A1 (fr) 2012-05-11 2013-11-14 Abbott Laboratories Combinaison de bêta-hydroxy-bêta-méthylbutyrate et de bêta-alanine destinée à augmenter le débit musculaire
ES2795665T3 (es) 2012-09-14 2020-11-24 Abbott Lab Procedimientos para aumentar la funcionalidad cerebral utilizando 2-fucosil-lactosa
DK2708145T3 (en) 2012-09-14 2016-07-18 Abbott Lab Nutritional Compositions for Use in Methods to Modulate Corticosterone Levels in Psychologically Stressed Individuals
EP2708146A1 (fr) 2012-09-17 2014-03-19 Abbott Laboratories, Inc. Composition nutritionnelle pour femmes enceintes avec un profil de glucose et d'insuline bénéfiques
WO2014078544A1 (fr) 2012-11-14 2014-05-22 Abbott Laboratories Compositions et procédés pour améliorer la sécurité à long terme des formules pour nourrissons en poudre
WO2014099904A1 (fr) 2012-12-17 2014-06-26 Abbott Laboratories Procédés pour améliorer la fonction motrice, améliorer les capacités fonctionnelles et réduire la faiblesse musculaire chez un sujet
EP2745705A1 (fr) 2012-12-18 2014-06-25 Abbott Laboratories Usage nutritionnel d'oligosaccharides du lait humain
WO2014100022A1 (fr) 2012-12-18 2014-06-26 Abbott Laboratories Oligosaccharides alimentaires destinés à favoriser l'apprentissage et la mémorisation
CA2893217C (fr) 2012-12-18 2017-11-28 Abbott Laboratories Oligosaccharides du lait humain destines a ameliorer les symptomes du stress
CA2894897C (fr) 2012-12-20 2018-09-18 Abbott Laboratories Compositions nutritives utilisant des oligosaccharides du lait humain pour moduler l'inflammation
EP2745708A1 (fr) 2012-12-24 2014-06-25 Abbott Laboratories, Inc. Effet antidépresseur du ß-hydroxy-ß-methylbutyrate
US20160037817A1 (en) 2013-03-12 2016-02-11 Abbott Laboratories Composition comprising a multifunctional viscosity modifying agent
CN105431057A (zh) 2013-03-15 2016-03-23 雅培制药有限公司 维持和改善肌肉功能的方法
SG11201507047YA (en) 2013-03-15 2015-10-29 Abbott Lab Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate, casein phosphopeptide, and protein
CN105263321B (zh) 2013-03-28 2018-07-27 哥伦比亚大学纽约管理委员会 用omega-3甘油酯再灌注促进对用于移植的供体器官的保护
WO2014200961A1 (fr) 2013-06-10 2014-12-18 Abbott Laboratories Méthodes et compositions permettant d'améliorer les performances cognitives
WO2015048646A1 (fr) 2013-09-30 2015-04-02 Abbott Laboratories Protéines en poudre
BR112015005933A2 (pt) 2013-10-11 2017-07-04 Abbott Lab composição nutricional para mulher grávida com um perfil benéfico de glicose e insulina
CN103558296B (zh) * 2013-10-18 2015-03-04 中国农业大学 一种基于脂肪酸检测的动物源性饲料原料鉴别方法
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
WO2015077233A1 (fr) 2013-11-19 2015-05-28 Abbott Laboratories Procédés pour prévenir ou atténuer des réponses allergiques aiguës au moyen d'oligosaccharides de lait humain
EP2888950A1 (fr) 2013-12-24 2015-07-01 Abbott Laboratories Procédés pour traiter, prévenir ou réduire une neuro-inflammation ou une déficience cognitive
WO2015105981A2 (fr) 2014-01-09 2015-07-16 Abbott Laboratories Essentialité conditionnelle de hmb
CA2942732C (fr) 2014-04-08 2023-01-03 Abbott Laboratories Procedes pour ameliorer les reponses immunitaires innee des muqueuses a et/ou la detection d'agents pathogenes a l'aide d'oligosaccharides de lait humain
DE102015101273A1 (de) 2015-01-29 2016-08-04 Eberhard Karls Universität Tübingen Medizinische Fakultät Prophylaxe und Behandlung von frühgeburtlichkeitsassoziierten Entwicklungsstörungen
EP3442562B1 (fr) 2016-04-15 2022-09-21 Evive Biotechnology (Shanghai) Ltd Un dimère il-22 pour l'utilisation dans le traitement de l'entérocolite nécrosante
RU2665947C1 (ru) * 2017-07-13 2018-09-05 Атикат Магомедхановна Герейханова Способ лечения некротического энтероколита
MX2021014980A (es) 2019-06-07 2022-01-26 Abbott Lab Ingrediente nutricional con propiedades antiespumantes y de flujo.
WO2021207180A1 (fr) 2020-04-06 2021-10-14 Abbott Laboratories Formulations nutritionnelles pour la modulation de cytokines induites par la respiration
CN112137998A (zh) * 2020-10-10 2020-12-29 上海交通大学医学院附属新华医院 一种活性成分在制备防治坏死性小肠结肠炎药物中的应用
WO2022177965A1 (fr) 2021-02-16 2022-08-25 Abbott Laboratories Compositions nutritionnelles comprenant des oligosaccharides du lait humain et de l'immunoglobuline bovine
WO2022226311A1 (fr) 2021-04-23 2022-10-27 Abbott Laboratories Compositions nutritionnelles comprenant des oligosaccharides de lait humain et un constituant lipidique désigné d'amélioration de fonction pulmonaire
WO2022266058A1 (fr) 2021-06-14 2022-12-22 Abbott Laboratories Procédés et compositions pour le traitement des gaz
WO2023159093A1 (fr) 2022-02-16 2023-08-24 Abbott Laboratories Compositions nutritionnelles comprenant des oligosaccharides de lait maternel et de l'immunoglobuline bovine
WO2024064327A1 (fr) 2022-09-22 2024-03-28 Abbott Laboratories Oligosaccharides de lait humain pour améliorer la fonction de barrière hémato-encéphalique

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3374914D1 (en) 1982-04-12 1988-01-28 Univ Texas Methods and compositions for treating gastro-intestinal ulcer diesease
US4670285A (en) 1982-08-06 1987-06-02 The University Of Toronto Innovations Foundation Infant formula
US4784861A (en) 1986-11-24 1988-11-15 Cca Industries, Inc. Weight-control formulation
US5032585A (en) 1987-02-17 1991-07-16 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for surfactant replacement therapy
US5043329A (en) 1987-02-17 1991-08-27 Board Of Regents, University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US4950656A (en) 1987-02-17 1990-08-21 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US4918063A (en) * 1987-02-17 1990-04-17 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US5000975A (en) 1988-12-29 1991-03-19 American Home Products Corporation Randomized palm oil fat composition for infant formulas
US5116819A (en) * 1989-05-05 1992-05-26 Clintec Nutrition Co. Enteral diet for patients with pulmonary disease
US5658767A (en) 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
SG49307A1 (en) 1991-01-24 1998-05-18 Martek Corp Microbial oil mixtures and use thereof
WO1993020717A2 (fr) * 1992-04-13 1993-10-28 Research Corporation Technologies, Inc. Reduction de l'irritation gastro-intestinale de nouveaux-nes au moyen d'aliments specifiques
DE4407939A1 (de) * 1993-03-15 1994-09-22 Sueddeutsche Kalkstickstoff Verfahren zur Herstellung von fett- und cholesterinreduzierten pulverförmigen Produkten auf Eibasis
FR2721481B1 (fr) * 1994-06-27 1996-09-06 Inst Rech Biolog Sa Nouvelles compositions diététiques à base de phospholipides et leur utilisation comme complément nutritionnel.
DK0784437T3 (da) 1994-10-05 1999-04-19 Milupa Gmbh & Co Kg Phospholipidholdig fedtblanding med LCP-fedtsyrer
JPH09201A (ja) * 1995-06-23 1997-01-07 Akikuni Yakida 炎症性腸疾患用食品
US5917068A (en) 1995-12-29 1999-06-29 Eastman Chemical Company Polyunsaturated fatty acid and fatty acid ester mixtures free of sterols and phosphorus compounds
US5790138A (en) 1996-01-16 1998-08-04 Monolithic System Technology, Inc. Method and structure for improving display data bandwidth in a unified memory architecture system

Also Published As

Publication number Publication date
EP1039892B1 (fr) 2004-04-28
BR9807443A (pt) 2000-04-25
AU6176998A (en) 1998-09-09
TR199902023T2 (xx) 2001-09-21
DK1039892T3 (da) 2004-08-30
DE69823548D1 (de) 2004-06-03
CN1269718A (zh) 2000-10-11
HUP0300236A3 (en) 2003-09-29
NZ337039A (en) 2001-06-29
PL343902A1 (en) 2001-09-10
CN1200701C (zh) 2005-05-11
AU732903B2 (en) 2001-05-03
EP1039892A2 (fr) 2000-10-04
NO994052L (no) 1999-10-20
IL131126A0 (en) 2001-01-28
ATE265207T1 (de) 2004-05-15
NO994052D0 (no) 1999-08-23
CA2281706C (fr) 2008-08-05
RU2199317C2 (ru) 2003-02-27
ES2219871T3 (es) 2004-12-01
CA2281706A1 (fr) 1998-08-27
JP2001516343A (ja) 2001-09-25
SK112399A3 (en) 2000-12-11
TWI230607B (en) 2005-04-11
WO1998036745A2 (fr) 1998-08-27
PT1039892E (pt) 2004-09-30
ID22744A (id) 1999-12-09
HK1034033A1 (en) 2001-10-12
DE69823548T2 (de) 2005-02-24
HUP0300236A2 (hu) 2003-06-28
WO1998036745A3 (fr) 2002-10-03
US6306908B1 (en) 2001-10-23

Similar Documents

Publication Publication Date Title
IL131126A (en) Compositions for reducing the incidence of necrotizing enterocolitis and the preparation thereof
Vidgren et al. Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men
DK1121115T4 (da) PUFA-tilskud
DE69622722D1 (de) Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselssyndroms
PL190841B1 (pl) Syntetyczna kompozycja lipidowa i jej zastosowanie do wytwarzania pokarmu dla niemowląt
EP2255668A3 (fr) Production et utilisation d'une fraction riche en lipide polaire contenant des acides gras hautement insaturés oméga 3 et/ou oméga 6 de microbes, de semences génétiquement modifiées et d'organismes marins
MX9806001A (es) Formula enteral o complemento alimenticio que contiene acidos araquidonico y docosahexaenoico.
AU677318B2 (en) A lipidic composition intended for use as a food or in food products
TW200744463A (en) Nutritional supplement containing long-chain polyunsaturated fatty acids
CO5550401A2 (es) Mezclas lipidas y productos alimenticios que contienen acido graso oleico y acidos grasos omega-6 diseñados para aumentar el nivel de lipido intramiocelular
DK1027831T3 (da) Stabiliseret fedtstofsammensætning, fremgangsmåde til fremstilling deraf og ernæringsprodukt indeholdende denne
ATE454820T1 (de) Neuartige fettpulver
Weber et al. Lipids in infant formulas and human milk fat substitutes
Hassam The influence of α-linolenic acid (18: 3ω3) on the metabolism of γ-linolenic acid (18: 3ω6) in the rat
JPWO2004108870A1 (ja) 油脂臭の新規脱臭法及びその組成物
OGUNLEIYE et al. Effect of fish oil and safflower oil in common Japanese diet on human plasma fatty acid composition
Sandoval et al. Omega-3 in the Prevention of Cardiovascular Diseases
Thi et al. Fatty acid, the lipid classes, phospholipid composition of the mussels\(\textit {Beguina semiorbiculata}\) from Nam Du and Phu Quoc islands, Kien Giang province, Vietnam
Renuka et al. EFFECT OF OMEGA 3 FATTY ACID IN PERIODONTITIS
Nettleton Omega-3 and Omega-6 Polyunsaturated Fatty Acids in the American Diet.
Milin et al. Polar lipid fatty acid composition changes induced by lipid supplemented diets associated with mice liver regeneration
EEL et al. ENZYMATIC ENRICHMENT OF DOCOSAHEXAENOIC ACID (DHA) IN

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees